[改良FOLFOX6方案治疗老年结直肠癌患者的疗效]

[Efficacy of m-FOLFOX6 therapy for colorectal cancer in elderly patients].

作者信息

Young Kim Woo, Maeda Kiyoshi, Noda Eiji, Fukunaga Shinya, Inoue Toru, Kaizaki Ryoji, Shinto Osamu, Wada Koji, Nakano Taeko, Hirakawa Kosei

机构信息

Dept. of Surgical Oncology, Attached Hospital in Ambulatory Chemotherapy Center, Osaka City University.

出版信息

Gan To Kagaku Ryoho. 2007 Nov;34(11):1833-6.

PMID:18030018

Abstract

Combination chemotherapy of oxaliplatin, fluorouracil/leucovorin (FOLFOX) has reportedly become a standard regimen for colorectal cancer. In this study, we investigated the efficacies and adverse effects of modified FOLFOX6 (m-FOLFOX6) regimen in elderly patients. Thirty-nine patients with colorectal cancer, who received m-FOLFOX6 in our institution, were studied. Ten of the 39 patients, were older than 70 (elderly patients). Efficacies and adverse effects of m-FOLFOX6 were compared between patients over 70 years of age and those younger than 69 (younger patients). In terms of the response rate, there were no differences between the older and younger elderly patients. Moreover, the grade and frequency of adverse events were similar between them. We concluded that m-FOLFOX6 may bring about the same response rate in older and younger elderly patients. Moreover, m-FOLFOX6 may be given safely regardless of patient age.

摘要

据报道，奥沙利铂联合氟尿嘧啶/亚叶酸钙（FOLFOX）化疗已成为结直肠癌的标准治疗方案。在本研究中，我们调查了改良FOLFOX6（m-FOLFOX6）方案在老年患者中的疗效和不良反应。对在我院接受m-FOLFOX6治疗的39例结直肠癌患者进行了研究。39例患者中有10例年龄超过70岁（老年患者）。比较了70岁以上患者和69岁以下患者（年轻患者）m-FOLFOX6的疗效和不良反应。在缓解率方面，老年和年轻患者之间没有差异。此外，他们之间不良事件的分级和频率相似。我们得出结论，m-FOLFOX6在老年和年轻患者中可能产生相同的缓解率。此外，无论患者年龄如何，m-FOLFOX6都可以安全给药。